HONG KONG and SHANGHAI, China and FLORHAM PARK, NJ, April 11, 2023 (GLOBE NEWSWIRE) – HUTCHMED (China) Limited (“Hutchmed“) (Nasdaq/AIM: HCM, HKEX: 13) announced today that new and updated clinical and non-clinical data on five HUTCHMED investigational drug candidates will be presented during the 2023 American Association for Cancer Research Annual Meeting (AACR 2023). , taking place April 14-19, 2023 in Orlando, Florida.
Savolitinib
| Title: | A multicenter phase II study of savolitinib in patients with MET-amplified adenocarcinoma of the gastroesophageal junction or gastric cancer | |
| Main author: | Lin Shen, MD, Beijing University Cancer Clinic and Institute | |
| Type: | Poster presentation | |
| session number: | PO.CT02.01 – Phase II clinical trials 1 | |
| Abstract link: | https://www.abstractsonline.com/pp8/#!/10828/presentation/10376 | |
| Title: | Plasma-based genomics at baseline and during treatment as a predictor of outcome in SAVANNAH: Savolitinib + osimertinib in EGFRm MET-overexpressed/amplified NSCLC post-osimertinib | |
| Main author: | Ryan J Hartmaier, Ph.D, AstraZeneca | |
| Type: | Poster presentation | |
| session number: | LB294/7 | |
| Abstract link: | https://www.abstractsonline.com/pp8/#!/10828/presentation/9996 |
Mesenchymal epithelial junction factor (“MET”) gene amplification is associated with poor prognosis in gastric cancer (“GC”) and adenocarcinoma of the gastroesophageal junction (“GEJ”). Savolitinib is a potent and highly selective oral MET tyrosine kinase inhibitor.
Here we reported the interim efficacy and safety data from a phase II study of savolitinib monotherapy in patients with MET-amplified advanced or metastatic GC/GEJ (NCT04923932). Additionally, the SAVANNAH Phase II study evaluated the benefit of plasma-based genomics with savolitinib in addition to osimertinib in post-osimertinib mutant MET-overexpressing/amplified non-small cell lung cancer (“NSCLC”) with mutant epidermal growth factor receptor (EGFR). The first presentation of the SAVANNEH results took place at the…
[ad_2]
Source story
